Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 1
2003 1
2004 1
2005 2
2006 1
2007 3
2008 2
2009 1
2011 2
2012 4
2013 5
2014 2
2015 15
2016 14
2017 10
2018 16
2019 13
2020 20
2021 18
2022 15
2023 17
2024 6
2025 19
2026 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

164 results

Results by year

Filters applied: . Clear all
Page 1
Comprehensive geriatric assessment (CGA) scale does not effectively identify elderly AML patients suitable for intensive induction chemotherapy - a multicenter study from Polish Adult Leukemia Group.
Budziszewska BK, Łomiak M, Barankiewicz J, Patkowska E, Helbig G, Bołkun Ł, Irga-Staniukiewicz A, Kiżewska A, Piekarska A, Koclęga A, Pluta A, Kuydowicz M, Kościołek-Zgódka S, Cichocka E, Malenda A, Wójcik K, Gromek T, Małecki P, Grosicki S, Giebel S, Wierzbowska A, Lech-Marańda E. Budziszewska BK, et al. Among authors: grosicki s. Ann Hematol. 2026 Feb 14;105(3):114. doi: 10.1007/s00277-026-06837-0. Ann Hematol. 2026. PMID: 41689641 Free PMC article.
The importance of autophagy in multiple myeloma.
Bednarczyk M, Dąbrowska-Szeja N, Łętowski D, Kozub A, Nasiek A, Grosicki S. Bednarczyk M, et al. Among authors: grosicki s. Expert Rev Anticancer Ther. 2026 Jan 13:1-14. doi: 10.1080/14737140.2025.2610261. Online ahead of print. Expert Rev Anticancer Ther. 2026. PMID: 41456322 Review.
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma.
Costa LJ, Bahlis NJ, Perrot A, Nooka AK, Lu J, Pawlyn C, Mina R, Caeiro G, Kentos A, Hungria V, Reece D, Niu T, Mylin AK, Hansen CT, Teipel R, Besemer B, Dimopoulos MA, Zamagni E, Yoshihara S, Kim K, Min CK, Geerts P, Van Leeuwen-Segarceanu E, Tyczynska A, Reguera JL, Johansson M, Hansson M, Turgut M, Grey M, Sidana S, Rodriguez-Otero P, Martinez-Lopez J, Hashmi H, Carson R, Kobos R, Sun W, Lantz K, Seifert A, Briseno-Toomey D, O'Rourke L, Rubin M, Vieyra D, Kang L, Mateos MV; MajesTEC-3 Trial Investigators. Costa LJ, et al. N Engl J Med. 2026 Feb 19;394(8):739-752. doi: 10.1056/NEJMoa2514663. Epub 2025 Dec 9. N Engl J Med. 2026. PMID: 41363801 Clinical Trial.
Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Woyach JA, Qiu L, Grosicki S, Wrobel T, Capra M, Czyz J, Yi S, Eom KS, Panovská A, Jurczak W, Laribi K, Jacobasch L, Baker R, Agajanian R, Berkovits A, Özcan M, Lepretre S, Coombs CC, Cramer P, Lewis KL, Hill M, Bao K, Bian Y, De Batista Ribeiro SR, Bhandari NR, Ruppert AS, Leow CC, Wierda WG. Woyach JA, et al. Among authors: grosicki s. J Clin Oncol. 2026 Feb 20;44(6):476-485. doi: 10.1200/JCO-25-02477. Epub 2025 Dec 7. J Clin Oncol. 2026. PMID: 41353787 Free PMC article. Clinical Trial.
A plain language summary of the CEPHEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for people with newly diagnosed multiple myeloma who are not expected to receive a stem cell transplant.
Usmani SZ, Facon T, Hungria V, Bahlis NJ, Venner CP, Braunstein M, Pour L, Martí JM, Basu S, Cohen YC, Matsumoto M, Suzuki K, Hulin C, Grosicki S, Legiec W, Beksac M, Maiolino A, Takamatsu H, Perrot A, Turgut M, Ahmadi T, Liu W, Wang J, Chastain K, Vermeulen J, Krevvata M, Lopez-Masi L, Carey J, Rowe M, Carson R, Zweegman S. Usmani SZ, et al. Among authors: grosicki s. Future Oncol. 2025 Oct;21(24):3115-3138. doi: 10.1080/14796694.2025.2560134. Epub 2025 Oct 7. Future Oncol. 2025. PMID: 41058194 Free PMC article.
Outcomes after transition from ibrutinib to zanubrutinib in patients with Waldenström macroglobulinemia from the ASPEN study.
García-Sanz R, Owen RG, Jurczak W, Dimopoulos MA, McCarthy H, Cull G, Opat SS, Castillo JJ, Kersten MJ, Wahlin BE, Grosicki S, Prathikanti R, Tian T, Allewelt H, Cohen AC, Tam CS. García-Sanz R, et al. Among authors: grosicki s. Blood Adv. 2025 Dec 23;9(24):6538-6546. doi: 10.1182/bloodadvances.2024015596. Blood Adv. 2025. PMID: 40924923 Free PMC article. Clinical Trial.
Erratum: Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321).
Sharman JP, Munir T, Grosicki S, Roeker LE, Burke JM, Chen CI, Grzasko N, Follows G, Mátrai Z, Sanna A, Qiu L, Feng R, Hua VM, Jurczak W, Ritgen M, Yi S, Bosch F, Coombs CC, Bao K, Patel V, Liu B, Compte L, Guntur A, Wang DY, Hill M, Leow CC, Ghia P, Barr PM. Sharman JP, et al. Among authors: grosicki s. J Clin Oncol. 2025 Sep;43(25):2841. doi: 10.1200/JCO-25-01700. Epub 2025 Jul 29. J Clin Oncol. 2025. PMID: 40729625 No abstract available.
164 results